NASDAQ:ATXS Astria Therapeutics (ATXS) Stock Price, News & Analysis $11.12 -0.36 (-3.14%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$10.99▼$11.6250-Day Range$8.97▼$12.3652-Week Range$4.26▼$16.90Volume244,363 shsAverage Volume699,962 shsMarket Capitalization$610.63 millionP/E RatioN/ADividend YieldN/APrice Target$25.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Astria Therapeutics alerts: Email Address Astria Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside126.6% Upside$25.20 Price TargetShort InterestBearish8.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.66) to ($1.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.45 out of 5 starsMedical Sector485th out of 910 stocksPharmaceutical Preparations Industry228th out of 426 stocks 4.6 Analyst's Opinion Consensus RatingAstria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAstria Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Astria Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.38% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Astria Therapeutics has recently increased by 10.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATXS. Previous Next 2.8 News and Social Media Coverage News SentimentAstria Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Astria Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for ATXS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Astria Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.66) to ($1.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astria Therapeutics is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Astria Therapeutics is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Astria Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis new buy indicator has the internet shook. In the last few weeks we’ve seen countless people talking about a totally new stock indicator called Platform X… It identifies the markets strongest stocks, then delivers customized buy signals for those stocks… Even as the market stalled out it nailed several calls including a 100%+ winner on Newmont mining… At first we thought this was some sort of hocus pocus indicator… But it turned out to be a very viable tool for trading today’s market action… Which is the reason for today's email…To check it out, just follow this link here. About Astria Therapeutics Stock (NASDAQ:ATXS)Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Read More ATXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXS Stock News HeadlinesAugust 30, 2024 | finance.yahoo.comAstria Therapeutics to Present at Upcoming Bradykinin SymposiumAugust 29, 2024 | finance.yahoo.comAstria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare ConferenceSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 28, 2024 | finance.yahoo.comATXS Sep 2024 10.000 call (ATXS240920C00010000)August 14, 2024 | markets.businessinsider.comEvercore ISI Keeps Their Buy Rating on Astria Therapeutics (ATXS)August 13, 2024 | markets.businessinsider.comBuy Rating for Astria Therapeutics: Strong Financials and Promising Drug PipelineAugust 12, 2024 | finance.yahoo.comAstria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary AngioedemaAugust 12, 2024 | finance.yahoo.comAstria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 7, 2024 | finance.yahoo.comAstria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare ConferenceJuly 29, 2024 | markets.businessinsider.comBuy Rating on Astria Therapeutics: Anticipating STAR-0215’s Market Impact and Patient Quality of Life ImprovementJuly 29, 2024 | msn.comTD Cowen Initiates Coverage of Astria Therapeutics (ATXS) with Buy RecommendationJune 24, 2024 | seekingalpha.comAstria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded FieldJune 4, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Jefferies Healthcare ConferenceMay 24, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceMay 23, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology CongressMay 22, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Astria Therapeutics (ATXS)See More Headlines Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATXS CUSIPN/A CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees30Year Founded2008Price Target and Rating Average Stock Price Target$25.20 High Stock Price Target$35.00 Low Stock Price Target$16.00 Potential Upside/Downside+126.6%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.00% Return on Assets-31.20% Debt Debt-to-Equity RatioN/A Current Ratio21.86 Quick Ratio21.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.46 per share Price / Book2.49Miscellaneous Outstanding Shares54,913,000Free Float53,321,000Market Cap$610.63 million OptionableOptionable Beta0.73 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMs. Jill C. Milne Ph.D. (Age 56)Co-Founder, CEO, President & Director Comp: $938.78kMr. John RueschSenior Vice President of Pharmaceutical Sciences & Technical OperationsKey CompetitorsSolid BiosciencesNASDAQ:SLDBNeos TherapeuticsNASDAQ:NEOSImmuCellNASDAQ:ICCCFreeline TherapeuticsNASDAQ:FRLNCorrevio PharmaNASDAQ:CORVView All CompetitorsInsiders & InstitutionsLogos Global Management LPSold 1,744,960 shares on 8/27/2024Ownership: 0.911%Nantahala Capital Management LLCBought 675,000 shares on 8/20/2024Ownership: 1.229%Driehaus Capital Management LLCSold 15,057 shares on 8/16/2024Ownership: 3.187%Affinity Asset Advisors LLCBought 130,000 shares on 8/15/2024Ownership: 1.777%Susquehanna Fundamental Investments LLCBought 44,000 shares on 8/15/2024Ownership: 0.080%View All Insider TransactionsView All Institutional Transactions ATXS Stock Analysis - Frequently Asked Questions How have ATXS shares performed this year? Astria Therapeutics' stock was trading at $7.68 at the start of the year. Since then, ATXS stock has increased by 44.8% and is now trading at $11.12. View the best growth stocks for 2024 here. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its earnings results on Monday, August, 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.05. When did Astria Therapeutics' stock split? Shares of Astria Therapeutics reverse split before market open on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. Who are Astria Therapeutics' major shareholders? Top institutional investors of Astria Therapeutics include Millennium Management LLC (3.35%), Driehaus Capital Management LLC (3.19%), Affinity Asset Advisors LLC (1.78%) and Nantahala Capital Management LLC (1.23%). Insiders that own company stock include Perceptive Advisors Llc and Andrew Komjathy. View institutional ownership trends. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
